Gastrointestinal Health References

1Sperber AD, Bangdiwala SI, Drossman DA, Ghoshal UC, Simren M, Tack J, Whitehead WE, Dumitrascu DL, Fang X, Fukudo S, Kellow J, Okeke E, Quigley EMM, Schmulson M, Whorwell P, Archampong T, Adibi P, Andresen V, Benninga MA, Bonaz B, Bor S, Fernandez LB, Choi SC, Corazziari ES, Francisconi C, Hani A, Lazebnik L, Lee YY, Mulak A, Rahman MM, Santos J, Setshedi M, Syam AF, Vanner S, Wong RK, Lopez-Colombo A, Costa V, Dickman R, Kanazawa M, Keshteli AH, Khatun R, Maleki I, Poitras P, Pratap N, Stefanyuk O, Thomson S, Zeevenhooven J, Palsson OS. Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study. Gastroenterology. 2021 Jan;160(1):99-114.e3. doi: 10.1053/j.gastro.2020.04.014. Epub 2020 Apr 12. PMID: 32294476.

2Lazarus, J.V., Mark, H.E., Anstee, Q.M. et al. Advancing the global public health agenda for NAFLD: a consensus statement. Nat Rev Gastroenterol Hepatol (2021). https://doi.org/10.1038/s41575-021-00523-4

3Chen J, Wu L, Yang G, Zhang C, Liu X, Sun X, Chen X, Wang N. The influence of PM2.5 exposure on non-alcoholic fatty liver disease. Life Sci. 2021 Apr 1;270:119135. doi: 10.1016/j.lfs.2021.119135. Epub 2021 Jan 26. PMID: 33513397.

4Cano R, Pérez JL, Dávila LA, Ortega Á, Gómez Y, Valero-Cedeño NJ, Parra H, Manzano A, Véliz Castro TI, Albornoz MPD, Cano G, Rojas-Quintero J, Chacín M, Bermúdez V. Role of Endocrine-Disrupting Chemicals in the Pathogenesis of Non-Alcoholic Fatty Liver Disease: A Comprehensive Review. Int J Mol Sci. 2021 May 1;22(9):4807. doi: 10.3390/ijms22094807. PMID: 34062716; PMCID: PMC8125512.

5Malan-Muller S, Valles-Colomer M, Raes J, Lowry CA, Seedat S, Hemmings SMJ. The Gut Microbiome and Mental Health: Implications for Anxiety- and Trauma-Related Disorders. OMICS. 2018 Feb;22(2):90-107. doi: 10.1089/omi.2017.0077. Epub 2017 Aug 2. PMID: 28767318.

6Roth NC, Kim A, Vitkovski T, Xia J, Ramirez G, Bernstein D, Crawford JM. Post-COVID-19 Cholangiopathy: A Novel Entity. Am J Gastroenterol. 2021 May 1;116(5):1077-1082. doi: 10.14309/ajg.0000000000001154. PMID: 33464757.

7Oshima T, Siah KTH, Yoshimoto T, Miura K, Tomita T, Fukui H, Miwa H. Impacts of the COVID-19 pandemic on functional dyspepsia and irritable bowel syndrome: A population-based survey. J Gastroenterol Hepatol. 2021 Jul;36(7):1820-1827. doi: 10.1111/jgh.15346. Epub 2020 Dec 1. PMID: 33197076; PMCID: PMC7753727.

8González-Acedo A, García-Recio E, Illescas-Montes R, Ramos-Torrecillas J, Melguizo-Rodríguez L, Costela-Ruiz VJ. Evidence from in vitro and in vivo studies on the potential health repercussions of micro- and nanoplastics. Chemosphere. 2021 Oct;280:130826. doi: 10.1016/j.chemosphere.2021.130826. Epub 2021 May 17. PMID: 34162123.

9Kosma, Christina & Lambropoulou, Dimitra & Albanis, Triantafyllos. (2016). Analysis, occurrence, fate and risks of proton pump inhibitors, their metabolites and transformation products in aquatic environment: A review. The Science of the total environment. 569-570. 732-750. 10.1016/j.scitotenv.2016.06.160.

10Australian Journal of General Practice Colume 50 Issue 10, October 2021 Retrieved from https://www1.racgp.org.au/ajgp/2021/october/updates-in-fatty-liver-disease

11Gill, M. G., & Majumdar, A. (2020). Metabolic associated fatty liver disease: Addressing a new era in liver transplantation. World journal of hepatology, 12(12), 1168–1181. https://doi.org/10.4254/wjh.v12.i12.1168

12Leon A Adams, Stuart K Roberts, Simone I Strasser, Suzanne E Mahady, Elizabeth Powell, Chris Estes, Homie Razavi, Jacob George